Pierre Combe

7PUBLICATIONS

64CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersMolecular medicine

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (7)

Sort by Publication Date:

|May 26, 2026

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Nov 24, 2025

Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Claudia Marchetti, Gwenael Ferron, Olivier Colomban

|May 28, 2025

GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Nicole Concin, Ioana Braicu, Pierre Combe

|Dec 14, 2024

Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

Florence Joly, Fernando Bazan, Delphine Garbay

|May 06, 2024

FASTOCH: Feasibility of Electronic Patient-Reported Outcomes in Older Patients With Cancer-A Multicenter Prospective Study.

Mathilde Cancel, Carine Sauger, Julie Biogeau

|Dec 04, 2023

Case Report of Probable DRESS Syndrome Associated with Ribociclib.

Florian Carneiro, Marine Bove, Frédérique Beau-Salinas

Pageof 2

Frequent Collaborators

Eric Pujade-Lauraine

Mathilde Cancel

Isabelle Ray-Coquard

Florence Joly

Frédéric Selle

François Audenet

Florence Brunet-Possenti

1 joint publications

Julia Sanchez

1 joint publications

Lucie Peuvrel

1 joint publications

Florian Carneiro

Frequent Collaborators

Eric Pujade-Lauraine

Mathilde Cancel

Isabelle Ray-Coquard

Florence Joly